Investors: Press Releases

Press Releases

October 6, 2020
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
September 23, 2020
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
June 1, 2020
NexImmune to Present at the Jefferies Virtual Healthcare Conference
January 8, 2020
NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
December 19, 2019
Neximmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
December 2, 2019
NexImmune Management to Present at Upcoming Conferences
October 30, 2019
NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
September 19, 2019
NexImmune and the Multiple Myeloma Research Foundation (MMRF) discuss collaborative opportunities to advance promising new therapies
June 4, 2019
NexImmune Management Presents at the Jefferies Healthcare Conference
April 29, 2019
Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials
Displaying 51 - 60 of 66